相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes
H. Masuda et al.
ANNALS OF ONCOLOGY (2014)
Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection
A. Romero et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2014)
Sequential F-18-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy
Bas B. Koolen et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer
Philip M. Spanheimer et al.
AMERICAN JOURNAL OF SURGERY (2013)
Predictive Factors Determining Neoadjuvant Chemotherapy Outcomes in Breast Cancer - a Single Center Experience
Yang Yu et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer
Nobuaki Matsubara et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response
E. H. Lips et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Acceptable but Limited Efficacy of Capecitabine-Based Doublets in the First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Pilot Study
Yuqian Liao et al.
CHEMOTHERAPY (2013)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Hiroko Masuda et al.
CLINICAL CANCER RESEARCH (2013)
Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer
G. C. Zhang et al.
CURRENT ONCOLOGY (2013)
Time to stop operating on breast cancer patients with pathological complete response?
D. Rea et al.
EJSO (2013)
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II-III invasive breast cancer: the OOTR-N001 study
Louis W. C. Chow et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: Long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials
Frederik Marme et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer
Yi Yin et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2013)
Clinical Efficacy of Including Capecitabine in Neoadjuvant Chemotherapy for Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Qiuyun Li et al.
PLOS ONE (2013)
The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients
Masako Tamaki et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2013)
Retrospective Analysis of Neoadjuvant Chemotherapy for Breast Cancer in Turkish Patients
Berna Bozkurt Duman et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry
Seho Park et al.
BREAST (2012)
Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy Distinct patterns of response according to ER expression
Hyeong-Gon Moon et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy
Nehmat Houssami et al.
EUROPEAN JOURNAL OF CANCER (2012)
Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer
Jae-Heon Jeong et al.
INVESTIGATIONAL NEW DRUGS (2012)
Impact of Immunohistochemistry-Based Molecular Subtype on Chemosensitivity and Survival in Patients with Breast Cancer Following Neoadjuvant Chemotherapy
Changhoon Yoo et al.
JOURNAL OF BREAST CANCER (2012)
Defining the Benefits of Neoadjuvant Chemotherapy for Breast Cancer
Anne F. Schott et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Breast Feeding, Parity and Breast Cancer Subtypes in a Spanish Cohort
Carmen M. Redondo et al.
PLOS ONE (2012)
Neoadjuvant chemotherapy in breast cancer-insights from the German experience
Gunter von Minckwitz
BREAST CANCER (2012)
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy
Abigail S. Caudle et al.
BREAST CANCER RESEARCH (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Impact of Breast Cancer Molecular Subtypes on Locoregional Recurrence in Patients Treated with Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer
Michael O. Meyers et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
Peter A. Fasching et al.
BMC CANCER (2011)
Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer
Jing Li et al.
ONCOLOGIST (2011)
The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy
M. E. Straver et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Jens Huober et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer
Seung Il Kim et al.
ONCOLOGY (2010)
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial
Judith Hugh et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Basal vs. luminal a breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers
Ezzeldin Ibrahim et al.
MEDICAL ONCOLOGY (2009)
The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes
Lisa A. Carey et al.
CLINICAL CANCER RESEARCH (2007)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
Lisa A. Carey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
AU Buzdar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Good clinical response of breast cancers to neoa uvant chemoendocrine therapy is associated with improved overall survival
SJ Cleator et al.
ANNALS OF ONCOLOGY (2005)
分享论文
